Beyond prostate-specific antigen: alternate serum markers

Ramírez, Michelle; Nelson, Eric; Evans, Christopher P.

doi:10.1038/pcan.2008.2

Cited by 33 publications

(34 citation statements)

References 144 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The ideal PCa biomarkers should be prostate specific, readily detectable in the body fluids, reproducibly measured and analysed, and can effectively differentiate among normal, benign and cancerous prostatic diseases as well as have cogent correlation to clinical data. [5,11] In the present study, serum tPSA and f/tPSA were significantly higher in the PCa than in the control groups and they can significantly be influenced by the tumor metastasizing. IGF-1 serum level was slightly increased and IGFBP-3 level was slightly decreased in patients with PCa, but they did not differentiate between PCa patients and control individuals; thus, no association of PCa risk were observed with prediagnostic serum concentrations of IGF-1, IGFBP-3 which may be attributed to the function of IGFBP-3 as a substrate for PSA.…”

Section: Discussionsupporting

confidence: 45%

“…There is a necessity to improve current methods for early detection and/or diagnosis of PCa and to distinguish men at risk for carcinogenesis. [5] Screening can detect disease in its early or asymptomatic stage; in addition, screening tests of malignant tumors must have high sensitivity to detect the disease with sufficient specificity to protect patients with false-positive results from uncalled-for diagnostic interventions. [6] A single polypeptide, prostate specific antigen (PSA), exists in diverse molecular forms.…”

Section: Introductionmentioning

confidence: 99%

“…[29] Inconsistencies may be attributed to the transient and reversible process of neuroendocrine differentiation (NED) in most malignant prostate tumors; thus, these NE molecules are not constantly detectable. [5,30] This study is dedicated to evaluate the validity of IGF-1, IGFBP-3, CgA and combination with PSA in diagnosis of patients with localized and metastatic PCa. The secondary objective was to compare the advantage of these markers in differentiation of PCa patients.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

Saleh¹,

Adly²,

Nassir³

2017

JCMT

View full text Add to dashboard Cite

Aim: Prostate cancer (PCa) is the second most prevalent male cancer worldwide and designated the sixth most frequent male cancer in Arab countries. Although prostate specific antigen (PSA) has become the best and most valuable biomarker for screening of PCa, elevated levels of PSA can reflect the presence of malignant cells but can overlap with benign prostatic diseases. There is a necessity to develop and improve current tools for early detection and diagnosis of PCa. This study was done to evaluate the validation of serum insulin-like growth factor-1 (IGF-1), IGF binding protein-3 (IGFBP-3), chromogranin A (CgA) and combination with PSA in treatment of benign prostatic hyperplasia (BPH) and PCa patients. Methods: The study included 72 patients with PCa, 70 BPH patients and 56 healthy male subjects of matched age. Full history and clinical data were recorded for all subjects. Results: Serum PSA attained sensitivity of 84% at 82% specificity with an accuracy of 83%, although IGF-1, IGFBP-3 and CgA did not recognize PCa patients. Conclusion: Combinations of IGF-1 and IGFBP-3 biomarkers with PSA were effectively differentiated between PCa and control groups as well as improving the overall value of sensitivity, specificity and diagnostic accuracy of PCa to 85% and 86% for IGF-1/PSA and IGFP-3/PSA respectively. Key words:Prostate cancer, benign prostatic hyperplasia, insulin-like growth factor-1, IGF binding protein-3, chromogranin A ABSTRACTArticle history:

show abstract

Section: Discussionsupporting

confidence: 45%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

Saleh¹,

Adly²,

Nassir³

2017

JCMT

View full text Add to dashboard Cite

show abstract

“…Few as urokinase-type plasminogen activator system, prostate membrane-specific antigen, hepatocyte growth factor, MIC-1, EGFR family (c-erbB-1 (EGFR), c-erbB-2 (HER2/neu), c-erbB-3 (HER3) and c-erbB-4 (HER4) [11] have shown their equal potency in diagnosis as well as prognosis. More recently Dwivedi et al [12] have proposed circulating serum interleukin-18 as a diagnostic biomarker and interleukin-10 for prognosis.…”

Section: Proteomicsmentioning

confidence: 99%

Non-Invasive Biomarker in Prostate Carcinoma: A Novel Approach

et al. 2013

View full text Add to dashboard Cite

“…[11][12][13][14][15] The polycomb group (PcG) of proteins BMI1, EZH2, and SIRT1 are characteristic components of the polycomb repression complex 1, 2 and 4, respectively, that modify chromatin. Recent studies suggested a direct influence of increased polycomb proteins on altered DNA-methylation patterns and hence gene silencing in prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Inverse association of p16INK4a and p14ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer

Verdoodt

Sommerer

et al. 2011

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

BACKGROUND: Promoter hypermethylation is an important epigenetic mechanism in the regulation of several key modulators of prostate carcinoma progression. Recent studies suggest that the polycomb-group (PcG) protein BMI1 may have an impact on epigenetic regulation of several targets, including the CDKN2a locus. METHODS:In this study, we investigated the association of BMI1 expression, promoter methylation of CDKN2a (p16INK4a and p14 ARF ) and TMS1 with pathological variables (Gleason score, TNM stage, perineural invasion) in prostate cancer (PCa). RESULTS: Methylation of p16INK4a and p14 ARF revealed an inverse association with Gleason score 7b and Gleason score 6. No significant association could be demonstrated for BMI1 -overexpression and promoter methylation of p16INK4a , p14 ARF and TMS1 as well as pT category.CONCLUSIONS: Our data suggest that the CDKN2a locus is a switch in PCa with methylation of p16INK4a being a marker for more aggressive tumours of Gleason score 7b, but no association with BMI overexpression was observed.

show abstract

Beyond prostate-specific antigen: alternate serum markers

Cited by 33 publications

References 144 publications

Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

Combination of insulin-like growth factor-1, IGF binding protein-3, chromogranin A and prostate specific antigen can improve the detection of prostate cancer

Non-Invasive Biomarker in Prostate Carcinoma: A Novel Approach

Inverse association of p16INK4a and p14ARF methylation of the CDKN2a locus in different Gleason scores of prostate cancer

Contact Info

Product

Resources

About